Berkeley UC
From 2007.igem.org
(Difference between revisions)
m |
|||
| (14 intermediate revisions not shown) | |||
| Line 1: | Line 1: | ||
<html> | <html> | ||
| + | <style> | ||
| + | #apDiv3 { | ||
| + | position:absolute; | ||
| + | left:10px; | ||
| + | top:-108px; | ||
| + | width:101px; | ||
| + | height:87px; | ||
| + | z-index:900; | ||
| + | } | ||
| + | </style> | ||
<link rel="stylesheet" href="http://www.davidtulga.com/iGEM_Berkeley_Stylesheet.css" type="text/css" /> | <link rel="stylesheet" href="http://www.davidtulga.com/iGEM_Berkeley_Stylesheet.css" type="text/css" /> | ||
<script type="text/javascript" src="http://www.davidtulga.com/flash.js"></script> | <script type="text/javascript" src="http://www.davidtulga.com/flash.js"></script> | ||
| + | |||
| + | <div id="apDiv3"><a href="https://2007.igem.org/Main_Page" title="iGEM 2007" alt="iGEM 2007"><img name="Coverlogo" src="https://static.igem.org/mediawiki/2007/0/0e/Coverlogojpeg.jpg" width="101" height="87" alt="iGEM 2007"></a></div> | ||
<table cellpadding="0" cellspacing="0" border="0" align="left" width="280" height="220" id="Header_Table" class="table_header" bgcolor="#8A0202"><tr><td id="Header_Table_TD" class="td_table_header" bgcolor="#8A0202"> | <table cellpadding="0" cellspacing="0" border="0" align="left" width="280" height="220" id="Header_Table" class="table_header" bgcolor="#8A0202"><tr><td id="Header_Table_TD" class="td_table_header" bgcolor="#8A0202"> | ||
| Line 10: | Line 22: | ||
</tr> | </tr> | ||
</table> | </table> | ||
| - | <img src="https://static.igem.org/mediawiki/2007/ | + | <img src="https://static.igem.org/mediawiki/2007/d/da/BerkiGEM2007-Bactoblood_text.jpg" border="0" id="Bactoblood_Header_Text_Img"> |
| - | <p>The necessity of inexpensive, disease-free, and universally compatible blood substitutes is undisputed. There are currently no blood substitutes approved for use in the US or the UK, and whole blood is almost always in short supply. Developing countries have the greatest need for blood transfusions, yet many lack the necessary donation and storage infrastructure and the required pool of healthy donors. To address this problem, we are developing a cost-effective red blood cell substitute constructed from engineered <i>E. coli</i> bacteria. Our system | + | <p><span id="Intro_Text">The necessity of inexpensive, disease-free, and universally compatible blood substitutes is undisputed. There are currently no blood substitutes approved for use in the US or the UK, and whole blood is almost always in short supply. Developing countries have the greatest need for blood transfusions, yet many lack the necessary donation and storage infrastructure and the required pool of healthy donors. To address this problem, we are developing a cost-effective red blood cell substitute constructed from engineered <i>E. coli</i> bacteria. Our system is designed to safely transport oxygen in the bloodstream without inducing sepsis, and to be stored for prolonged periods in a freeze-dried state.<br /><br /></span></p> |
| - | <p><b><i>Support for Berkeley iGEM 2007 was generously provided by | + | <p><span id="Support_Text"><b><i>Support for Berkeley iGEM 2007 was generously provided by |
| - | SynBERC and The Camille and Henry Dreyfus Foundation, Inc.</i> </b> | + | SynBERC and The Camille and Henry Dreyfus Foundation, Inc.</i></b> |
| - | </p><hr /> | + | </span></p><hr /> |
<p> </p> | <p> </p> | ||
<p align="left"> | <p align="left"> | ||
| - | <table width="100%" id="table2" border="2" cellpadding="0" style="padding: 0px; width: 100%; color: navyblue; background-color: lightblue;"> | + | <table width="100%" id="table2" border="2" cellpadding="0" style="padding: 0px; width: 100%; color: navyblue; background-color: lightblue;" id="Main_Icons_Table"> |
<!--<tr> | <!--<tr> | ||
<td class="tdheadL"> </td> | <td class="tdheadL"> </td> | ||
| Line 48: | Line 60: | ||
<tr> | <tr> | ||
<td class="tdboxes"> | <td class="tdboxes"> | ||
| - | <a href="https://2007.igem.org/BerkiGEM2007Present3"><img border="0" src="https://static.igem.org/mediawiki/2007/ | + | <a href="https://2007.igem.org/BerkiGEM2007Present3"><img border="0" src="https://static.igem.org/mediawiki/2007/8/8d/Berk-Icon-Controller.png" width="121" height="121"></a></td> |
<td class="tddesc"><b><a href="https://2007.igem.org/BerkiGEM2007Present3">The Controller</a></b><p><i>The Controller | <td class="tddesc"><b><a href="https://2007.igem.org/BerkiGEM2007Present3">The Controller</a></b><p><i>The Controller | ||
is an integrated genetic circuit comprised of two plasmids that allows | is an integrated genetic circuit comprised of two plasmids that allows | ||
| Line 70: | Line 82: | ||
<a href="https://2007.igem.org/BerkiGEM2007Present2"><img border="0" src="https://static.igem.org/mediawiki/2007/c/ce/Berk-Icon-Freeze-Drying.png" width="121" height="121"></a></td> | <a href="https://2007.igem.org/BerkiGEM2007Present2"><img border="0" src="https://static.igem.org/mediawiki/2007/c/ce/Berk-Icon-Freeze-Drying.png" width="121" height="121"></a></td> | ||
<td class="tddesc"><b><a href="https://2007.igem.org/BerkiGEM2007Present2">Freeze Drying</a></b><p><i>To | <td class="tddesc"><b><a href="https://2007.igem.org/BerkiGEM2007Present2">Freeze Drying</a></b><p><i>To | ||
| - | enable preservation of our bacteria for | + | enable preservation of our bacteria for prolonged periods, |
we are including the ability to produce the compounds | we are including the ability to produce the compounds | ||
hydroxyectoine and trehalose that will enable our bacteria to | hydroxyectoine and trehalose that will enable our bacteria to | ||
| Line 79: | Line 91: | ||
<p><br /></p> | <p><br /></p> | ||
| - | <table width="100%" id="table3" border="2" style="padding: 0px; width: 100%; color: navyblue; background-color: #ffffaa;"> | + | |
| + | <table width="100%" id="table2" border="2" cellpadding="0" style="padding: 0px; width: 100%; color: navyblue; background-color: lightblue;" id="Secondary_Icons_Table"> | ||
| + | <!--<tr> | ||
| + | <td class="tdheadR" colspan="2"> | ||
| + | <h3>Other Stuff</h3></td> | ||
| + | </tr>--> | ||
| + | <tr> | ||
| + | <td class="tdsmallboxes"><a href="https://2007.igem.org/BerkiGEM2007Present6"><img border="0" src="https://static.igem.org/mediawiki/2007/8/8b/Berk-Icon-Small-Patents.png" width="83" height="83"></a></td> | ||
| + | <td class="tddesc" style="padding-bottom: 0px; padding-top: 7px;"><b><a href="https://2007.igem.org/BerkiGEM2007Present6">Human Practices</a></b><p><i>An examination of the landscape of patents and the patentablilty of Bactoblood where its parts are in an open source forum and the challenges associated with current patenting practices for synthetic biology.</i></td> | ||
| + | </tr> | ||
| + | <tr> | ||
| + | <td class="tdsmallboxes"><a href="https://2007.igem.org/Berkeley_Individual_Contributions"><img border="0" src="https://static.igem.org/mediawiki/2007/0/06/Berk-Icon-Small-References.png" width="83" height="83"></a></td> | ||
| + | <td class="tddesc"><b><a href="https://2007.igem.org/Berkeley_Individual_Contributions">Individual Contributions</a></b><p><i>The specific contributions made by each team member and advisor.</i></td> | ||
| + | </tr> | ||
| + | <tr> | ||
| + | <td class="tdsmallboxes"><a href="https://2007.igem.org/BerkiGEM2007_Resources"><img border="0" src="https://static.igem.org/mediawiki/2007/d/da/Berk-Icon-Small-Resources.png" width="83" height="83"></a></td> | ||
| + | <td class="tddesc"><b><a href="https://2007.igem.org/BerkiGEM2007_Resources">Team Resources</a></b><p><i>Organizational spreadsheets, useful tools and links.</i></td> | ||
| + | </tr> | ||
| + | <tr> | ||
| + | <td class="tdsmallboxes"><a href="https://2007.igem.org/BerkiGEM2007_Notebooks"><img border="0" src="https://static.igem.org/mediawiki/2007/7/77/Berk-Icon-Small-Notebooks.png" width="83" height="83"></a></td> | ||
| + | <td class="tddesc"><b><a href="https://2007.igem.org/BerkiGEM2007_Notebooks">Team Notebooks</a></b><p><i>The team members' daily logs of our research.</i></td> | ||
| + | </tr> | ||
| + | </table> | ||
| + | |||
| + | <p><br /></p> | ||
| + | |||
| + | <table width="100%" id="table3" border="2" style="padding: 0px; width: 100%; color: navyblue; background-color: #ffffaa;" id="Team_Members_Table"> | ||
<tr> | <tr> | ||
<td class="tdheadR" style="background-color: #ffffaa;"> | <td class="tdheadR" style="background-color: #ffffaa;"> | ||
| Line 85: | Line 123: | ||
</tr> | </tr> | ||
<tr> | <tr> | ||
| - | <td class="tddesc | + | <td class="tddesc"><b>Advisors</b><br /> |
| - | + | ||
<a href="/igem07/index.php/John_Dueber" title="John Dueber"> | <a href="/igem07/index.php/John_Dueber" title="John Dueber"> | ||
John Dueber</a> <font face="Arial">•</font> | John Dueber</a> <font face="Arial">•</font> | ||
| Line 94: | Line 131: | ||
Adam Arkin</a> <font face="Arial">•</font> | Adam Arkin</a> <font face="Arial">•</font> | ||
<a href="https://keaslinglab.lbl.gov/wiki/index.php/Main_Page" title="https://keaslinglab.lbl.gov/wiki/index.php/Main Page" rel="nofollow"> | <a href="https://keaslinglab.lbl.gov/wiki/index.php/Main_Page" title="https://keaslinglab.lbl.gov/wiki/index.php/Main Page" rel="nofollow"> | ||
| - | Jay Keasling</a><br / | + | Jay Keasling</a><br /> |
<p><b>Teaching Assistants</b><br /> | <p><b>Teaching Assistants</b><br /> | ||
<a href="/igem07/index.php/Farnaz_Nowroozi" title="Farnaz Nowroozi"> | <a href="/igem07/index.php/Farnaz_Nowroozi" title="Farnaz Nowroozi"> | ||
| Line 133: | Line 170: | ||
</tr> | </tr> | ||
</table> | </table> | ||
| - | + | <div id="Footer_Stuff"> </div> | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
</html> | </html> | ||
Latest revision as of 05:42, 17 July 2008
The necessity of inexpensive, disease-free, and universally compatible blood substitutes is undisputed. There are currently no blood substitutes approved for use in the US or the UK, and whole blood is almost always in short supply. Developing countries have the greatest need for blood transfusions, yet many lack the necessary donation and storage infrastructure and the required pool of healthy donors. To address this problem, we are developing a cost-effective red blood cell substitute constructed from engineered E. coli bacteria. Our system is designed to safely transport oxygen in the bloodstream without inducing sepsis, and to be stored for prolonged periods in a freeze-dried state.
Support for Berkeley iGEM 2007 was generously provided by SynBERC and The Camille and Henry Dreyfus Foundation, Inc.
The System's Components |
|
 |
Oxygen Transport Our system is designed to produce Hemoglobin, Heme, and the necessary chaperones and detoxifying agents to promote the transport of oxygen throughout the bloodstream. We also investigated alternates to hemoglobin and other strategies for its production. |
 |
The Chassis Our bacterial chassis has been heavily modified to remove its sepsis-inducing toxicity, immunogenic factors, and ability to grow within the bloodstream, as well as promote its ability to last longer in the bloodstream by masking it from the immune system. |
 |
The Controller The Controller is an integrated genetic circuit comprised of two plasmids that allows stable maintenance of the system's various operons on a large single-copy plasmid in a dormant state. Upon induction, the copy number of the operons and their transcription increase 100-fold resulting in a dramatic increase in protein expression. |
 |
Genetic Self-Destruct To prevent chance of infection or unwanted proliferation after hemoglobin production, we have engineered a genetic self-destruct mechanism whereby when induced, the bacterial cell will express a genetic material-degrading toxin which kills the cell, but leaves it physically intact. |
 |
Freeze Drying To enable preservation of our bacteria for prolonged periods, we are including the ability to produce the compounds hydroxyectoine and trehalose that will enable our bacteria to survive freeze-drying intact. This will dramatically increase shelf-life and decrease transport costs. |
 |
Human Practices An examination of the landscape of patents and the patentablilty of Bactoblood where its parts are in an open source forum and the challenges associated with current patenting practices for synthetic biology. |
 |
Individual Contributions The specific contributions made by each team member and advisor. |
 |
Team Resources Organizational spreadsheets, useful tools and links. |
 |
Team Notebooks The team members' daily logs of our research. |
Team Members |
| Advisors John Dueber • Christopher Anderson • Adam Arkin • Jay Keasling Teaching Assistants Support Undergraduate Researchers High School Students |
